Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients
© 2017 Future Medicine Ltd. Aim: To develop a population pharmacokinetic model and identify sources of variability, genetic and nongenetic factors, of tenofovir. Methods: The ABCC2 and ABCC4 polymorphisms were genotyped in 342 patients. A nonlinear mixed effects model was used to develop the populat...
Saved in:
Main Authors: | , , , , , , , |
---|---|
Format: | Journal |
Published: |
2018
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85034419484&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/56682 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
id |
th-cmuir.6653943832-56682 |
---|---|
record_format |
dspace |
spelling |
th-cmuir.6653943832-566822018-09-05T03:51:29Z Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients Kanokrat Rungtivasuwan Anchalee Avihingsanon Narukjaporn Thammajaruk Siwaporn Mitruk David M. Burger Kiat Ruxrungtham Chonlaphat Sukasem Baralee Punyawudho Biochemistry, Genetics and Molecular Biology Pharmacology, Toxicology and Pharmaceutics © 2017 Future Medicine Ltd. Aim: To develop a population pharmacokinetic model and identify sources of variability, genetic and nongenetic factors, of tenofovir. Methods: The ABCC2 and ABCC4 polymorphisms were genotyped in 342 patients. A nonlinear mixed effects model was used to develop the population pharmacokinetic model and investigate the influence of these polymorphisms and other patient specific covariates on the pharmacokinetics of tenofovir. Results: The estimated glomerular filtration rate calculated by the Cockcroft and Gault equation, concomitant use of lopinavir/ritonavir and ABCC4 3463A>G polymorphism were associated with tenofovir apparent oral clearance (CL/F). The use of lopinavir/ritonavir decreased tenofovir CL/F by 25%. Patients carrying ABCC4 3463 AG or GG had a tenofovir CL/F 11% higher than those with genotype AA. Conclusion: Renal function, co-medication and genetic variation impact the pharmacokinetics of tenofovir. These factors should be taken into consideration to guide the individual tenofovir disoproxil fumarate dosage regimen in Thai HIV-infected patients. 2018-09-05T03:28:53Z 2018-09-05T03:28:53Z 2017-11-01 Journal 17448042 14622416 2-s2.0-85034419484 10.2217/pgs-2017-0128 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85034419484&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/56682 |
institution |
Chiang Mai University |
building |
Chiang Mai University Library |
country |
Thailand |
collection |
CMU Intellectual Repository |
topic |
Biochemistry, Genetics and Molecular Biology Pharmacology, Toxicology and Pharmaceutics |
spellingShingle |
Biochemistry, Genetics and Molecular Biology Pharmacology, Toxicology and Pharmaceutics Kanokrat Rungtivasuwan Anchalee Avihingsanon Narukjaporn Thammajaruk Siwaporn Mitruk David M. Burger Kiat Ruxrungtham Chonlaphat Sukasem Baralee Punyawudho Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients |
description |
© 2017 Future Medicine Ltd. Aim: To develop a population pharmacokinetic model and identify sources of variability, genetic and nongenetic factors, of tenofovir. Methods: The ABCC2 and ABCC4 polymorphisms were genotyped in 342 patients. A nonlinear mixed effects model was used to develop the population pharmacokinetic model and investigate the influence of these polymorphisms and other patient specific covariates on the pharmacokinetics of tenofovir. Results: The estimated glomerular filtration rate calculated by the Cockcroft and Gault equation, concomitant use of lopinavir/ritonavir and ABCC4 3463A>G polymorphism were associated with tenofovir apparent oral clearance (CL/F). The use of lopinavir/ritonavir decreased tenofovir CL/F by 25%. Patients carrying ABCC4 3463 AG or GG had a tenofovir CL/F 11% higher than those with genotype AA. Conclusion: Renal function, co-medication and genetic variation impact the pharmacokinetics of tenofovir. These factors should be taken into consideration to guide the individual tenofovir disoproxil fumarate dosage regimen in Thai HIV-infected patients. |
format |
Journal |
author |
Kanokrat Rungtivasuwan Anchalee Avihingsanon Narukjaporn Thammajaruk Siwaporn Mitruk David M. Burger Kiat Ruxrungtham Chonlaphat Sukasem Baralee Punyawudho |
author_facet |
Kanokrat Rungtivasuwan Anchalee Avihingsanon Narukjaporn Thammajaruk Siwaporn Mitruk David M. Burger Kiat Ruxrungtham Chonlaphat Sukasem Baralee Punyawudho |
author_sort |
Kanokrat Rungtivasuwan |
title |
Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients |
title_short |
Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients |
title_full |
Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients |
title_fullStr |
Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients |
title_full_unstemmed |
Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients |
title_sort |
pharmacogenetics-based population pharmacokinetic analysis of tenofovir in thai hiv-infected patients |
publishDate |
2018 |
url |
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85034419484&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/56682 |
_version_ |
1681424737675247616 |